PROTEOMICS ALLIANCE FOR CANCER

癌症蛋白质组学联盟

• 批准号: 7602895
• 负责人: GILBERT S OMENN
• 金额: $ 6.98万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2008-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7602895
• 关键词: 3-Dimensional; Affinity; Aftercare; Albumins; Antibodies; Biological Markers; Biological Sciences; Bone Marrow Transplantation; Clinical; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Detection; Development; Diagnostic; Disease; Early Diagnosis; Economic Development; Equipment; Fractionation; Funding; Grant; Institution; Label; Laboratories; Liquid substance; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Michigan; National Center for Research Resources; Organ; Patients; Plasma; Process; Prostate; Protein Microchips; Proteins; Proteomics; Research; Research Institute; Research Personnel; Resolution; Resources; Scheme; Serum; Site; Source; Specimen; System; Technology; Time; Tissues; United States National Institutes of Health; Universities; base; cancer cell; cancer proteomics; cyanine dye 5; graft vs host disease; improved; neoplastic cell; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Proteomics Alliance for Cancer (PAC) is supported by the Michigan Life Sciences Corridor (MLSC)/Michigan Economic Development Corporation, and affiliated with the UM NCRR Center The Proteomics Alliance for Cancer has brought together key laboratories in the cancer proteomics domain at the University of Michigan, Van Andel Research Institute, local firms, MLSC Core Technology Alliance, and the UM NCRR Center. The PAC has demonstrated the usefulness for clinical studies of the Cy3/Cy5 double-labeling of paired clinical specimens (before and after treatment, or before and after development of complications), combined with our 3-dimensional fractionation and mass spec analysis scheme. Novel findings were obtained for graft-versus-host disease after bone marrow transplantation, a treatment for certain kinds of cancers. PAC served as the beta-site for the new Beckman-Coulter PF 2D proteomics equipment and as one of several beta-sites for the new Agilent immuno-affinity column for depletion of the six most abundant proteins in plasma/serum. We made major contributions to the improvements of these new products and have had the benefit of early use of the equipment. Both companies have introduced these products commercially. We concluded that depletion of albumin and several other highly abundant proteins in plasma can markedly improve the resolution and sensitivity of detection of less abundant proteins, including those which may be derived from organs and tissues that are sites of origin of disease processes. We are pursuing the challenging aim of enhancing throughput in liquid-based separation systems. At the same time, we are utilizing the existing LC systems to create 2000 fractions from tumor cell lysates for protein microarrays both at VAI and UM that have promise for diagnostic applications. Substantial progress has been made collaboratively in the Haab lab at Van Andel and the Hanash lab at UM on prostate and lung cancer cell protein microarrays for detection of circulating auto-antibodies against these proteins in the sera of patients with prostate cancer or lung cancer, respectively. These studies have major potential to identify and validate useful biomarkers for earlier diagnosis of these and other cancers.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 密歇根州生命科学走廊（MLSC）/密歇根州经济发展公司的蛋白质组学联盟（PAC）得到了UM NCRR中心的支持 蛋白质组学联盟的癌症联盟将密歇根大学，范安德尔研究所，当地公司，MLSC Core Technology Alliance和UM NCRR中心的癌症蛋白质组学领域的关键实验室汇总在一起。 PAC证明了对配对临床标本的CY3/CY5双标记的临床研究的有用性（治疗前后，治疗后或并发症发生并发症发生之前和之后），并结合我们的3维分馏和质量分析方案。 骨髓移植后获得了新发现的移植物抗宿主病，这是某些类型的癌症的治疗方法。 PAC是新的Beckman-Coulter PF 2D蛋白质组学设备的β位点，也是新的Agilent免疫亲和力柱的几个β位点之一，用于耗尽血浆/血清中六种最丰富的蛋白质。我们为这些新产品的改进做出了重大贡献，并从早期使用设备方面受益。两家公司都在商业上推出了这些产品。 我们得出的结论是，血浆中白蛋白和其他几种高度丰富的蛋白质的耗竭可以显着提高检测较少丰富蛋白的分辨率和敏感性，包括可能来自疾病过程起源的器官和组织的蛋白质。 我们正在追求在基于液体的分离系统中增强吞吐量的具有挑战性的目标。同时，我们利用现有的LC系统从VAI和UM的蛋白质微阵列中创建2000个分数，这些分数有望诊断应用。 在Van Andel的Haab实验室和UM的Hanash Lab在前列腺和肺癌细胞蛋白微阵列上进行了协同取得的重大进展，以检测循环 针对前列腺癌或肺癌患者血清中这些蛋白质的自身抗体。这些研究具有识别和验证有用的生物标志物以早期诊断这些和其他癌症的主要潜力。